ASTALLTD
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Astal Laboratories To Buy 100% Of Sriven Pharmachem
Oct 10 (Reuters) - Astal Laboratories Ltd ASTB.BO:
ASTAL LABORATORIES LTD - TO BUY 100% OF SRIVEN PHARMACHEM
ASTAL LABORATORIES LTD - ACQUISITION COST SET AT 2.77 BILLION RUPEES
Source text: ID:nBSE5qss1z
Further company coverage: ASTB.BO
(([email protected];;))
Oct 10 (Reuters) - Astal Laboratories Ltd ASTB.BO:
ASTAL LABORATORIES LTD - TO BUY 100% OF SRIVEN PHARMACHEM
ASTAL LABORATORIES LTD - ACQUISITION COST SET AT 2.77 BILLION RUPEES
Source text: ID:nBSE5qss1z
Further company coverage: ASTB.BO
(([email protected];;))
Astal Laboratories Buys Pharmaceutical Intermediates Manufacturing Plant Of Shree Venus Health Sciences
Oct 16 (Reuters) - Astal Laboratories Ltd ASTB.BO:
BUYS PHARMACEUTICAL INTERMEDIATES MANUFACTURING PLANT OF SHREE VENUS HEALTH SCIENCES
ACQUISITION FOR 96 MILLION RUPEES
Source text for Eikon: ID:nBSE8jmNVm
Further company coverage: ASTB.BO
(([email protected];;))
Oct 16 (Reuters) - Astal Laboratories Ltd ASTB.BO:
BUYS PHARMACEUTICAL INTERMEDIATES MANUFACTURING PLANT OF SHREE VENUS HEALTH SCIENCES
ACQUISITION FOR 96 MILLION RUPEES
Source text for Eikon: ID:nBSE8jmNVm
Further company coverage: ASTB.BO
(([email protected];;))
Macro International Approved Raising Of Funds
Dec 20 (Reuters) - Macro International Ltd MACR.BO:
APPROVED RAISING OF FUNDS
TO ISSUE 4.9 MILLION SHARES AT ISSUE PRICE OF 30 RUPEES EACH
Source text for Eikon: ID:nBSE3hdVHw
Further company coverage: MACR.BO
(([email protected];))
Dec 20 (Reuters) - Macro International Ltd MACR.BO:
APPROVED RAISING OF FUNDS
TO ISSUE 4.9 MILLION SHARES AT ISSUE PRICE OF 30 RUPEES EACH
Source text for Eikon: ID:nBSE3hdVHw
Further company coverage: MACR.BO
(([email protected];))
Macro International To Consider Issue Of Shares On Preferential Basis
Dec 15 (Reuters) - Macro International Ltd MACR.BO:
TO CONSIDER ISSUE OF SHARES ON PREFERENTIAL BASIS
Further company coverage: MACR.BO
(([email protected];))
Dec 15 (Reuters) - Macro International Ltd MACR.BO:
TO CONSIDER ISSUE OF SHARES ON PREFERENTIAL BASIS
Further company coverage: MACR.BO
(([email protected];))
Macro International Ventures Into Contrast Media Business, Introduces Lopromide Usp For Bulk Drug Manufacturing
Aug 24 (Reuters) - Macro International Ltd MACR.BO:
VENTURES INTO CONTRAST MEDIA BUSINESS, INTRODUCES LOPROMIDE USP FOR BULK DRUG MANUFACTURING
Source text for Eikon: ID:nBSE70y44l
Further company coverage: MACR.BO
(([email protected];))
Aug 24 (Reuters) - Macro International Ltd MACR.BO:
VENTURES INTO CONTRAST MEDIA BUSINESS, INTRODUCES LOPROMIDE USP FOR BULK DRUG MANUFACTURING
Source text for Eikon: ID:nBSE70y44l
Further company coverage: MACR.BO
(([email protected];))
Macro International Says Kommera Harish Resigns As Chief Executive Officer
June 19 (Reuters) - Macro International Ltd MACR.BO:
KOMMERA HARISH RESIGNS AS CHIEF EXECUTIVE OFFICER
Source text for Eikon: ID:nBSEc9ldVh
Further company coverage: MACR.BO
(([email protected];))
June 19 (Reuters) - Macro International Ltd MACR.BO:
KOMMERA HARISH RESIGNS AS CHIEF EXECUTIVE OFFICER
Source text for Eikon: ID:nBSEc9ldVh
Further company coverage: MACR.BO
(([email protected];))
Events:
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Astal Laboratories do?
Macro International Ltd, incorporated in 1993, is a company engaged in exporting goods such as bridles, halters, rugs, saddles, strip leather, reins, shoes, and bell boots, along with sales via departmental stores.
Who are the competitors of Astal Laboratories?
Astal Laboratories major competitors are Rajlaxmi Industries, Rajnish Retail, Remedium Lifecare, Novelix Pharma, Gautam Exim, Yash Chemex, Ashnisha Industries. Market Cap of Astal Laboratories is ₹88 Crs. While the median market cap of its peers are ₹90 Crs.
Is Astal Laboratories financially stable compared to its competitors?
Astal Laboratories seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Astal Laboratories pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Astal Laboratories latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Astal Laboratories allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Inventory, Accounts Receivable
How strong is Astal Laboratories balance sheet?
Balance sheet of Astal Laboratories is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Astal Laboratories improving?
Yes, profit is increasing. The profit of Astal Laboratories is ₹9.91 Crs for TTM, ₹8.93 Crs for Mar 2025 and ₹0.78 Crs for Mar 2024.
Is the debt of Astal Laboratories increasing or decreasing?
The net debt of Astal Laboratories is decreasing. Latest net debt of Astal Laboratories is ₹7.75 Crs as of Sep-25. This is less than Mar-25 when it was ₹9.81 Crs.
Is Astal Laboratories stock expensive?
Astal Laboratories is not expensive. Latest PE of Astal Laboratories is 8.85, while 3 year average PE is 96.8. Also latest EV/EBITDA of Astal Laboratories is 6.59 while 3yr average is 7.43.
Has the share price of Astal Laboratories grown faster than its competition?
Astal Laboratories has given better returns compared to its competitors. Astal Laboratories has grown at ~36.55% over the last 7yrs while peers have grown at a median rate of 29.08%
Is the promoter bullish about Astal Laboratories?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Astal Laboratories is 18.19% and last quarter promoter holding is 18.19%.
Are mutual funds buying/selling Astal Laboratories?
There is Insufficient data to gauge this.
